On March 19, 2021 Isofol Medical AB (publ) ("Isofol"), (Nasdaq First North Premier Growth Market: ISOFOL) reported that the independent Data Safety and Monitoring Board (iDSMB) has recommended continuation of the global Phase III AGENT study with 440 patients, in accordance with the study design for the drug candidate, arfolitixorin (Press release, Isofol Medical, MAR 19, 2021, View Source [SID1234576913]). Isofol expects the top line results for the AGENT study to be available during H1 2022.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The iDSMB recommendation follows a pre-scheduled interim analysis as part of the study design and was initiated when the 330th patient had been treated for 16 weeks and had two tumor evaluations. iDSMB evaluated safety and efficacy (ORR and PFS). The Company remains blinded to the interim analysis results.
"The recommendation from iDSMB is encouraging in many ways; first, it does not require us to recruit additional patients which enables us to keep our current timeline with the goal to submit a New Drug Application to FDA & EMA in H2 2022. Second, it is an additional confirmation that arfolitixorin shows no signs of increased toxicity which in combination with previous efficacy data strengthens our belief in arfolitixorin’s potential. Thirdly, we may be on the market in the US already in 2023", said Ulf Jungnelius, M.D, CEO of Isofol.
Arfolitixorin is evaluated in the AGENT study for the treatment of patients with first-line metastatic colorectal cancer (mCRC). The study is currently being conducted in Australia, Europe, Japan, Canada and the US in more than 90 clinics and includes a total of 440 patients.
This information is information that Isofol Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 18:10 CET on March 19, 2021.
About arfolitixorin
Arfolitixorin is Isofol’s proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. The drug candidate is currently being studied in a global Phase III study, AGENT. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit more patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.